Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes

Cost Effectiveness and Resource Allocation

Volumn 9, Issue , 2011, Pages

  McQueen, R Brett ^a   Ellis, Samuel L ^a   Campbell, Jonathan D ^a   Nair, Kavita V ^a   Sullivan, Patrick W ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b REGIS UNIVERSITY   (United States)

Author keywords

Continuous Glucose Monitoring; Cost effectiveness analysis; Cost utility analysis; Self Monitoring of Blood Glucose; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CONTINUOUS GLUCOSE MONITORING TECHNOLOGY; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTERMETHOD COMPARISON; MONTE CARLO METHOD; QUALITY OF LIFE; SELF MONITORING; SENSITIVITY ANALYSIS; UNITED STATES;

EID: 80052828858     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-9-13     Document Type: Article

References (25)

1. American Diabetes Association Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care 2008, 31(3):596-615. American Diabetes Association.
2. The Diabetes Control and Complications Trial Research Group The Effect Of Intensive Treatment Of Diabetes On The Development And Progression Of Long-Term Complications In Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine 1993, 329(14):977-986. The Diabetes Control and Complications Trial Research Group.
3. Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine 2005, 353(25):2643-2653. 2637991, 16371630.
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 2003, 290(16):2159-2167. 2622725, 14570951, Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes.
5. American Diabetes Association Standards of Medical Care in Diabetes-2009. Diabetes Care 2009, 32(Supplement 1):S13-S61. 2613589, 19118286, American Diabetes Association.
6. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of Improved Glycemic Control on Health Care Costs and Utilization. JAMA 2001, 285(2):182-189. 10.1001/jama.285.2.182, 11176811.
7. Schnell O, Hummel M, Weber C. Economic and Clinical Aspects of Diabetes Regarding Self-Monitoring of Blood Glucose. Diabetes Technology and Therapeutics 2008, 10(supplement 1).
8. Garg SK. Glucose Monitoring: An Important Tool for Improving Glucose Control and Reducing Hypoglycemia. Diabetes Technology & Therapeutics 2008, 10(s1):S-1-S-4.
9. Naik RG, Ellis SL. Self-Monitoring of Blood Glucose in Insulin-Requiring Type 2 Diabetes. Diabetes Technology & Therapeutics 2008, 10(s1):S-67-S-71. 10.1089/dia.2008.0030, 21919735.
10. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Continuous glucose monitoring and intensive treatment of type 1 diabetes. New England Journal of Medicine 2008, 359(14):1464-76. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
11. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technology & Therapeutics 2007, 9(3):203-10. 10.1089/dia.2007.0205, 21919735.
12. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006, 29(12):2730-2. 10.2337/dc06-1134, 17130215.
13. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care 2010, 33(6):1269-74. 10.2337/dc09-2042, 2875436, 20332354, The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.
14. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Current Medical Research & Opinion 2004, 20(Suppl 1):S27-40.
15. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research & Opinion 2004, 20(Suppl 1):S5-26.
16. The C.D.C. Cost-Effectiveness Group Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes. JAMA 2002, 287(19):2542-2551. 10.1001/jama.287.19.2542, 12020335, The C.D.C. Cost-Effectiveness Group.
17. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Annals of Internal Medicine 2004, 140(9):689-99.
18. Klein BE, Klein R, McBride PE, Cruickshanks KJ, Palta M, Knudtson MD, Moss SE, Reinke JO. Cardiovascular Disease, Mortality, and Retinal Microvascular Characteristics in Type 1 Diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Archives of Internal Medicine 2004, 164(17):1917-1924. 10.1001/archinte.164.17.1917, 15451768.
19. Wu SY, Sainfort F, Tollios JL, Fryback DG, Klein R, Klein BE. Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. Diabetes Care 1998, 21(5):725-731. 10.2337/diacare.21.5.725, 9589231.
20. The Absence of a Glycemic Threshold for the Development of Long-Term Complications: The Perspective of the Diabetes Control and Complications Trial. Diabetes 1996, 45(10):1289-1298.
21. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus. Annals of Internal Medicine 2004, 141(6):421-431.
22. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States. Medical Decision Making 2006, 26:410-420. 10.1177/0272989X06290495, 2634296, 16855129.
23. Gold M, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. 1996, New York: Oxford University Press.
24. Diabetes Mall for Continuous Glucose Monitoring. , http://www.diabetesnet.com/diabetes_technology/continuous_monitoring.php
25. Cusick M, Meleth AD, Agron E, Fisher MR, Reed GF, Knatterud GL, Barton FB, Davis MD, Ferris FL, Chew EY, . Early Treatment Diabetic Retinopathy Study Research Group Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care 2005, 28(3):617-25. 10.2337/diacare.28.3.617, 15735198, Early Treatment Diabetic Retinopathy Study Research Group.